{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:24:53Z","timestamp":1787117093305,"version":"build-2736575974"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Anti-amyloid treatment (AAT) with monoclonal antibodies represents a major therapeutic advance in early Alzheimer disease (AD), but its introduction has important and underappreciated implications for vascular neurology. Because many patients with AD also have cerebral amyloid angiopathy and other cerebrovascular pathology, AAT influences stroke diagnosis, acute reperfusion therapy, and long-term antithrombotic management. Clinical trials of lecanemab and donanemab enrolled highly selected patients with minimal baseline cerebrovascular pathology, limiting generalizability to real-world populations with prevalent vascular comorbidity. Amyloid-related imaging abnormalities, particularly vasogenic edema and microhemorrhages, constitute a central safety concern and may clinically mimic acute ischemic stroke, complicating emergency decision-making and increasing the risk of inappropriate intravenous thrombolysis (IVT). Emerging reports of intracerebral hemorrhage following IVT in treated patients underscore the need for revised acute stroke pathways and support consideration of mechanical thrombectomy when otherwise indicated, although AAT-specific safety data are lacking. Beyond the hyperacute phase of stroke, concomitant use of anticoagulants or dual antiplatelet therapy raises unresolved questions regarding hemorrhagic risk, particularly in patients with atrial fibrillation or those requiring complex antithrombotic regimens. Alternative strategies, including left atrial appendage closure, may be considered in selected patients, although evidence in AAT recipients remains limited. As AAT enters routine practice, multidisciplinary collaboration, dedicated imaging protocols, and prospective safety registries will be essential to integrate disease-modifying AD treatment with safe and effective cerebrovascular care.<\/jats:p>","DOI":"10.3389\/fneur.2026.1889769","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:36:08Z","timestamp":1787114168000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions"],"prefix":"10.3389","volume":"17","author":[{"given":"Matija","family":"Zupan","sequence":"first","affiliation":[{"name":"Department of Vascular Neurology, University Medical Centre Ljubljana","place":["Ljubljana, Slovenia"]},{"name":"Faculty of Medicine, University of Ljubljana","place":["Ljubljana, Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polona Rus","family":"Prelog","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana","place":["Ljubljana, Slovenia"]},{"name":"Centre for Clinical Psychiatry, University Psychiatric Clinic Ljubljana","place":["Ljubljana, Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica Gregori\u010d","family":"Kramberger","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana","place":["Ljubljana, Slovenia"]},{"name":"Department of Neurology, University Medical Centre Ljubljana","place":["Ljubljana, Slovenia"]},{"name":"Department of Neurobiology, Care Sciences and Society (NVS) Division of Clinical Geriatrics, Karolinska Institutet","place":["Huddinge, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senta","family":"Frol","sequence":"additional","affiliation":[{"name":"Department of Vascular Neurology, University Medical Centre Ljubljana","place":["Ljubljana, Slovenia"]},{"name":"Faculty of Medicine, University of Ljubljana","place":["Ljubljana, Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/STR.0000000000000480","article-title":"Vascular neurology considerations for antiamyloid immunotherapy: a science advisory from the American Heart Association","volume":"56","author":"Greenberg","year":"2025","journal-title":"Stroke"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"ref3","first-page":"512","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume-title":"JAMA","author":"Sims","year":"2023"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000545799","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer disease: intersocietal recommendations for their appropriate use in Switzerland","volume":"25","author":"Felbecker","year":"2025","journal-title":"Neurodegener Dis"},{"key":"ref5","year":"2025"},{"key":"ref6","year":"2025"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.14283\/jpad.2021.41","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.14283\/jpad.2023.41","article-title":"Editorial: clinical implementation of Lecanemab: challenges, questions and solutions","volume":"10","author":"Iwatsubo","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"ref9","year":"2025"},{"key":"ref10","year":"2025"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e70062","DOI":"10.1002\/alz.70062","article-title":"Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e70652","DOI":"10.1002\/alz.70652","article-title":"Real-world lecanemab adoption in Japan 1 year after launch: insights from 311 specialists on infrastructure and reimbursement barriers","volume":"21","author":"Sato","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.12779\/dnd.2024.23.4.165","article-title":"Lecanemab: appropriate use recommendations by Korean dementia association","volume":"23","author":"Park","year":"2024","journal-title":"Dement Neurocogn Disord"},{"key":"ref14","year":"2025"},{"key":"ref15","year":"2025"},{"key":"ref16","year":"2024"},{"key":"ref17","year":"2025"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e70186","DOI":"10.5694\/mja2.70186","article-title":"Cost-effectiveness of donanemab for early Alzheimer disease in Australia","volume":"224","author":"Gao","year":"2026","journal-title":"Med J Aust"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3390\/jcm13051245","article-title":"The impact of anti-amyloid immunotherapies on stroke care","volume":"13","author":"Bilodeau","year":"2024","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/BNM.BNM_14_23","article-title":"Monoclonal antibody therapy in Alzheimer\u2019s disease: an overview and vision","volume":"3","author":"Bentley","year":"2024","journal-title":"BNM"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"9529","DOI":"10.3390\/ijms26199529","article-title":"Anti-amyloid therapies for Alzheimer's disease: Progress, pitfalls, and the path ahead","volume":"26","author":"Papaliagkas","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple cerebral hemorrhages in a patient receiving Lecanemab and treated with t-PA for stroke","volume":"388","author":"Reish","year":"2023","journal-title":"N Engl J Med"},{"key":"ref24","year":"2024"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate Use Recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s10072-026-08829-4","article-title":"Regulatory, clinical, and post-marketing challenges of lecanemab for Alzheimer's disease: insights from real-world data","volume":"47","author":"Marano","year":"2026","journal-title":"Neurol Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2001123","article-title":"Endovascular thrombectomy with or without intravenous alteplase in acute stroke","volume":"382","author":"Yang","year":"2020","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1161\/STR.0000000000000406","article-title":"Endovascular treatment and thrombolysis for acute ischemic stroke in patients with premorbid disability or dementia: a scientific statement from the American Heart Association\/American Stroke Association","volume":"53","author":"Ganesh","year":"2022","journal-title":"Stroke"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1056\/NEJMoa2214403","article-title":"Trial of endovascular thrombectomy for large ischemic strokes","volume":"388","author":"Sarraj","year":"2023","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1056\/NEJMoa2314063","article-title":"Trial of thrombectomy for stroke with a large infarct of unrestricted size","volume":"390","author":"Costalat","year":"2024","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1056\/NEJMoa2408954","article-title":"Endovascular treatment for stroke due to occlusion of medium or distal vessels","volume":"392","author":"Psychogios","year":"2025","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1056\/NEJMoa2411668","article-title":"Endovascular treatment of stroke due to medium-vessel occlusion","volume":"392","author":"Goyal","year":"2025","journal-title":"N Engl J Med"},{"key":"ref33","year":"2024"},{"key":"ref34","year":"2024"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1136\/jnnp-2025-337386","article-title":"Risk of amyloid-related imaging abnormalities associated with anticoagulant therapy in patients with Alzheimer's disease treated with anti-amyloid monoclonal antibodies: a systematic review and meta-analysis","volume":"97","author":"Schlemm","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: Appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.tjpad.2025.100094","article-title":"Lecanemab for early Alzheimer's disease: appropriate use recommendations from the French federation of memory clinics","volume":"12","author":"Villain","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/23969873211012121","article-title":"European stroke organisation guideline on endarterectomy and stenting for carotid artery stenosis","volume":"6","author":"Bonati","year":"2021","journal-title":"Eur Stroke J"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1056\/NEJMoa2508800","article-title":"Medical management and revascularization for asymptomatic carotid stenosis","volume":"394","author":"Brott","year":"2026","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights","volume":"127","author":"Kornej","year":"2020","journal-title":"Circ Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimer's Res Ther"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.3791\/3671","article-title":"The WATCHMAN left atrial appendage closure device for atrial fibrillation","volume":"60","author":"M\u00f6bius-Winkler","year":"2012","journal-title":"J Vis Exp"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1016\/j.jacc.2015.04.025","article-title":"Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis","volume":"65","author":"Holmes","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e792","DOI":"10.1161\/STROKEAHA.121.037248","article-title":"Left atrial appendage closure in patients with atrial fibrillation and coexisting cerebral amyloid angiopathy","volume":"52","author":"Blanc","year":"2021","journal-title":"Stroke"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e210125","DOI":"10.1212\/WNL.0000000000210125","article-title":"Pearls and oy-sters: a patient on Lecanemab newly diagnosed with atrial fibrillation","volume":"103","author":"Ryan","year":"2024","journal-title":"Neurology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e0208710","DOI":"10.1371\/journal.pone.0208710","article-title":"Long term outcomes after left atrial appendage closure with the LARIAT device\u2014stroke risk reduction over five years follow-up","volume":"13","author":"Litwinowicz","year":"2018","journal-title":"PLoS One"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jtcvs.2011.07.052","article-title":"Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial","volume":"142","author":"Ailawadi","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1093\/europace\/eux211","article-title":"Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery","volume":"20","author":"Caliskan","year":"2018","journal-title":"Europace"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.3390\/jcm12175562","article-title":"Efficacy and safety of Oral factor XIa inhibitors in stroke prevention: a systematic review and Meta-analysis","volume":"12","author":"Palaiodimou","year":"2023","journal-title":"J Clin Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"Asundexian for secondary stroke prevention","volume":"394","author":"Sharma","year":"2026","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13024-023-00649-w","article-title":"Amyloid-\u03b2 (a\u03b2) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer's disease mice","volume":"18","author":"Taylor","year":"2023","journal-title":"Mol Neurodegener"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41582-024-01053-8","article-title":"Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms","volume":"21","author":"Greenberg","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1474-4422(25)00313-8","article-title":"Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study","volume":"24","author":"Boon","year":"2025","journal-title":"Lancet Neurol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease\u2014one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e70014","DOI":"10.1002\/trc2.70014","article-title":"Understanding recent advances in non-amyloid\/non-tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease","volume":"10","author":"Van Eldik","year":"2024","journal-title":"Alzheimers Dement (N Y)"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1889769\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:36:19Z","timestamp":1787114179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1889769\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":56,"alternative-id":["10.3389\/fneur.2026.1889769"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1889769","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1889769"}}